logo-loader
viewAdherium

Adherium Ltd partners with AstraZeneca to improve medication adherence

au_pharma_358.jpg

Adherium Ltd (ASX:ADR) will provide its Smartinhaler devices to AstraZeneca Australia for a commercial pilot program in patients with asthma and chronic obstructive pulmonary disease.

Smartinhaler is a touch-enabled device that provides alerts to improve medication adherence and health outcomes for patients.

AstraZeneca will use Adherium’s devices, mobile app and cloud platform and aims to show how these devices improve medication adherence in patients.

Notably, clinical studies in the past have proven that the Smartinhaler platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults.

Adherium is supplying the technology for this program under a long-term master supply and development agreement already entered into with AstraZeneca.

The company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.

Adherium will now look to accelerate its expansion in North America after the opening of its office in San Mateo, California earlier this month.

Adherium is well funded with $27.2 million in cash as at 30 June 2016.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Quick facts: Adherium

Price: 0.041 AUD

ASX:ADR
Market: ASX
Market Cap: $7.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PolarX encounters encouraging results in drilling at Alaska Range project

PolarX Ltd (ASX:PXX) managing director Frazer Tabeart updates Proactive on first drilling results from the Mars and Saturn prospects in the Alaska Range project in Alaska. The drilling at Mars intersected porphyry-style veins containing visible copper and molybdenum sulphides. Tabeart said...

1 hour, 50 minutes ago

2 min read